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Summary. Vascular dementia ccounts for approximately 
20% of all cases of dementia and for about 50% in 
subjects over 80 years. Thromboembolism with multiple 
cerebral infarcts was considered to be almost the only 
pathogenetic pathway of vascular dementia, with multi- 
infarct dementia s its clinical manifestation. However, 
there is a great heterogeneity of vascular dementia syn- 
dromes and pathological subtypes, as documented by the 
number of pathogenetic mechanisms now known to un- 
derlie the clinical picture. They include thromboem- 
bolism and extracerebral nd cerebral factors. Among 
the extracerebral factors are ischemic hypoxic dementia 
(i.e., dementia due to hypoperfusion), vasculitis, hyper- 
viscosity and abnormalities of hemostasis. Among the 
cerebral factors are lipohyalinosis, cerebral amyloid an- 
giopathy, disruption of the blood-brain barrier and al- 
tered regulation of cerebral blood flow. Therefore, the 
approach to vascular dementia should take the hetero- 
geneity into account. In this context, the importance of 
non-infarct type should be considered; subcortical white 
matter disorder seems to be a noteworthy common path- 
way of vascular dementia produced by various vascular 
mechanisms. Finally, the heterogeneity of the vascular 
mechanisms involved in vascular d~mentia - namely hy- 
poperfusion - might be a factor that can be positively 
influenced by targeted therapeutic ntervention. 
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Introduction 
Vascular dementia (VD) is currently considered to be the 
second type of dementia fter primary degenerative de- 
mentias, i.e., dementia of Alzheimer type (DAT), ac- 
counting for approximately 20% of all cases, versus 50% 
with DAT. There is a considerable increase in the preva- 
lence of VD with advancing age; in subjects over 80 years 
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figures reach and surpass prevalence rates for DAT [62]. 
VD is the commonest cause of dementia in Japan, being 
responsible for up to 50% of all clinical cases and for 
54%-65% of all autopsy-confirmed dementias world- 
wide [88]. While degenerative d mentias are currently un- 
treatable, there is, in contrast, a definite potential for the 
prevention and treatment of cerebrovascular diseases. 
The varied clinical presentations and the multiple 
causes of dementia syndrome make clinical diagnosis 
quite difficult. In 1984, a Work Group on the Diagnosis 
of Alzheimer's Disease established by the National Insti- 
tute of Neurological and Communicative Disorders and 
Stroke and the Alzheimer's Disease and Related Disor- 
ders Association [39] proposed widely used clinical for 
the diagnosis of DAT (Table 1). The main problem is 
that the diagnosis is an exclusion diagnosis. For VD, 
analogous criteria have been recently proposed which are 
summarized in Table 2. 
Belief in a multi-infarct origin of VD [26] is now pre- 
dominant, although a non-multi-infarct pathogenesis has 
been proposed by several investigators [7, 17, 53, 76-78]. 
Today, the term multi-infarct dementia (MID) seems in- 
adequate to cover the whole group of VD. Major cerebral 
loss due to multiple small or large cerebral infarcts is not 
essential for mental deterioration caused by vascular fac- 
tors, and increasing importance should be given to the 
diffuse subcortical involvement documented in post- 
mortem neurochemical [76, 77], histopathological [2,32] 
and brain imaging [16] studies. 
The aim of this review is to cover current knowledge 
about the different pathogenetic mechanisms underlying 
VD. As a background, the anatomy and pathophysiology 
of the cerebral circulation is first discussed. Finally, po- 
tential implications for future research are discussed. 
Vascular anatomy and physiopathologicai 
aspects of the brain 
The arterial blood supply of the brain is guaranteed by 
the internal carotid and the vertebral arteries, which 
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Table 1. Criteria for clinical diagnosis of Alzheimer's disease [39] 
Probable Alzheimer's disease 
1. Dementia established by clinical examination and documented by 
the Mini Mental Test, Blessed Dementia Scale or some similar 
examination and confirmed by neuropsychological tests 
2. Deficits in two or more areas of cognition 
Progressive worsening of memory and other cognitive functions 
3. No disturbances of consciousness 
4. Absence of systemic disorders or other brain diseases that of 
themselves could account for the progressive deficits in memory 
and cognition 
The diagnosis of probable Alzheimer's disease is supported by 
1. Progressive deterioration of specific ognitive functions uch as 
language (aphasia), motor skills (apraxia) and perception (agnosia) 
2. Impaired activities of daily living and altered patterns of behavior 
3. Family history of similar disorders, particularly if confirmed neu- 
ropathologically 
4. Laboratory results of: 
normal umbar puncture as evaluated by standard techniques 
normal pattern or non-specific changes in electroencephalogram, 
such as increased slow-wave activity 
evidence of cerebral atrophy on computed tomography (CT) with 
progression documented by serial observation 
Possible Alzheimer's disease 
1. Dementia syndrome, in the absence of other neurological, psychi- 
atric or systemic disorders sufficient to cause dementia, nd in the 
presence of variations in the onset, in the presentation r in the 
clinical course 
2. May be made in the presence of a second systemic or brain dis- 
order sufficient o produce dementia, which is not considered to 
be the cause of the dementia 
3. Should be used in research studies when a single, gradually pro- 
gressive severe cognitive deficit is identified in the absence of 
other identifiable cause 
Definite AIzheimer's disease 
1. Clinical criteria for probable Alzheimer's disease and histopatho- 
logical evidence obtained from a biopsy or autopsy 
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Table 2. Criteria for the clinical diagnosis of vascular dementia [55] 
Probable vascular dementia 
1. Dementia, preferably established by clinical examination and 
documented by neuropsychological testing: deficits should be 
severe nough to interfere with activities of daily living 
2. Cerebrovascular disease (CVD), definite by the presence of local 
signs on neurological examination and evidence of relevant CVD 
by brain imaging (CT or magnetic resonance imaging), including 
multiple large-vessel strokes or a single strategically placed in- 
farct, as well as multiple basal ganglia and white matter lacunes 
or extensive periventricular white matter lesions or combinations 
thereof 
3. A relationship between the above two disorders, manifested or 
inferred by the presence of one or more of the following: 
a. onset of dementia within 3 months following a recognized stroke 
b. abrupt deterioration i  cognitive function or fluctuating, step- 
wise progression of cognitive deficits 
Possible vascular dementia 
May be made in the presence of dementia with focal neurological 
signs but in the absence of brain imaging confirmation of definite 
CVD, or in the absence of a clear temporal relationship between 
dementia nd stroke or in patients with a subtle onset and variable 
course (plateau or improvement) of cognitive deficits and evidence 
of relevant CVD 
Definite vascular dementia 
1. Clinical criteria for probable vascular dementia 
2. Histopathological evidence of CVD obtained from biopsy or 
autopsy 
3. Absence of neurofibrillary tangles and neuritic plaques exceeding 
those expected for age 
4. Absence of another clinical or pathological disorder capable of 
producing dementia 
duced by all three cell types, an alterat ion in cellular 
function might be reflected in changed basal membrane 
function. 
anastomose intracranial ly under the basis cerebri to form 
the circle of  Willis. F rom this, a network of  lepto- 
meningeal arteries or iginate which encircle the surface of  
cerebral hemispheres. There is an analogous network of  
leptomeningeal rteries a round the brain and the cerebel- 
lum, which gives off  centr i fugal and centripetal vessels 
without anastomoses between them. This creates a sub- 
cortical watershed area that is part icular ly vulnerable to 
ischemia. At  the capi l lary level, cerebral vessels are made 
up of  three cell types: (1) the endothel ia l  cells sealed to- 
gether by tight junctions,  with no fenestrations and with 
a few pinocytic vesicles; (2) the pericytes, whose processes 
encompass the capi l lary walls (these share antigenic de- 
terminants with macrophages,  uggesting a possible im- 
munological  function); (3) the astrocytes, whose process- 
es surround the endothel ium. All  these cells synthesize 
the structural  components  of  the basal membrane which 
contr ibutes to the b lood-bra in  barr ier  (BBB), control  cel- 
lular migrat ion,  filter macromolecules in a highly selec- 
tive way and probab ly  influence ndothel ia l  cell functions 
[68], and support  capi l lary cells physically. Since the 
main components  o f  the basal  membrane (i:e., col lagen 
type IV, laminin, heparan sulfate proteoglycan) are pro- 
Blood brain barrier 
The BBB is a complex system of  anatomica l  structures 
with physicochemical  and b iochemical  propert ies that 
guarantee highly selective b lood-bra in  exchanges. Many  
studies have been performed to detect  he possible role of  
BBB changes in the pathogenesis  of  age-related involu- 
t i re phenomena,  with special emphas is  on the pathologi -  
cally aging brain. Impaired t ranspor t  of  crucial nutrients 
and metabol i tes to the brain or  the entry into central 
nervous system of circulating toxins or autoant ibod ies  
could be the basis of  aging bra in  dysfunctions.  Senes- 
cence seems to be associated with very subtle BBB 
changes, region and species specific, but several patho-  
logical condit ions (e.g., hypertens ion,  diabetes, cerebral  
ischemia) could further increase the damage [45]. Al- 
though there is no definite evidence for age-related BBB 
dysfunction, several studies have demonstrated altered 
integrity of  the BBB in DAT and  in VD. The observat ion 
that serum proteins (e.g., A4  protein)  can be detected in 
senile plaques, neurof ibr i l lary tangles and vascular  amy- 
loid supports the hypothesis that  BBB dysfunct ion is im- 
portant  in DAT pathogenesis [23, 73]. Two other  factors 
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should also be considered: (1) altered processing of amy- 
loid precursor by the endothelium ight cause the forma- 
tion of intracytoplasmic neurofibrillary tangles; (2) exu- 
dation of amyloid fibrils might lead to the formation of 
dystrophic neurites ("neurites reaction"). Another inter- 
esting hypothesis has been proposed by Scheibel and 
Duong [58]: "denervation microangiopathy" (irregular 
thickening of the vessel walls, infiltration of serum 
proteins) is observed in 90% of elderly patients uffering 
from DAT and these alterations might be the first mani- 
festation of a BBB defect in this type of dementia. The 
main source of the neural perivascular plexus is the locus 
coeruleus, which probably protects the BBB [27], and the 
cholinergic nuclei in the basal forebrain [60]. All these 
nuclei are altered in degenerative dementias. Injured 
BBB, due to an acute ischemic event or to chronic 
damage on cerebral microvessels, is more evident in VD 
[1, 82]. 
In VD, the presence of infarctual areas or diffuse 
damage of small arteries (lypohyalinosis) is considered to 
be the morphological basis for leakage of serum proteins 
into the cerebrospinal f uid compartment [1, 46, 82]. 
Several reports [29, 46] have shown restoration of BBB 
function a few weeks after a stroke episode not evolving 
into dementia. This finding, confirmed also by other in- 
vestigators [14, 37], together with the high albumin ratio 
observed in MID subjects, suggests permanent alteration 
of barrier function, reflecting a diffuse rather than a focal 
vessel wall disturbance. 
Factors regulating cerebral blood JTow 
Autoregulation is the capacity of the brain to maintain a 
constant cerebral blood flow at about 55 ml/100 g brain 
tissue per min over a wide range of arterial blood pressure 
(between 60 and t 70 mmHg in the normal adult) [36]. It 
is possible that this capacity decreases with age [86]. Ac- 
cording to the myogenic theory, the smooth muscles re- 
spond directly to variations in blood pressure. These may 
be of importance, because local accumulation of various 
substances with vasoconstrictor effects, such as brady- 
kinin, histamine and serotonin [57, 84], and substances 
with vasodilatator capacity, such as serotonin [72], affect 
vascular tone [75]. A third possibility is that autonomic 
neurons control vascular tone [38, 59]. This last includes 
not only local vasomotor effects but also a remote impact 
such as diaschisis [34]. Diaschisis, appearing as bilateral 
reduction of the hemispheric blood flow, has been report- 
ed for patients with unilateral cerebral infarcts [41, 42, 
61]. It has been suggested that all three mechanisms may 
play roles [24, 43]. 
If the blood pressure decreases below 60 mmHg, the 
autoregulation does not work and subcortical white mat- 
ter in particular isks destruction, while the grey matter 
regions are better preserved [21, 81]. However, with com- 
plete ischemia, grey matter is more heavily involved. In 
grey matter neurotransmitter metabolism is extremely 
sensitive to even short periods of hypoxia [48]. Although 
the autoregulation adapts to long-standing hypertension 
[65], the small vessels gradually become affected struc- 
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turally, with development of atherosclerosis and hyali- 
nosis further reducing their autoregulatory capacity. In 
addition, in patients with long-standing hypertension the 
risk of white lesions is increased, even at apparently nor- 
mal blood pressure levels [64]. 
Pathogenetic mechanisms 
A therosclerosis and thromboembolism 
Atherosclerosis is the most important cause of illness and 
death from cardiovascular disease. The cerebral vessels 
most commonly affected are the internal carotid arteries, 
the basilar artery, the middle and posterior cerebral arter- 
ies and the vertebral arteries, while the anterior cerebral, 
posterior communicating and cerebellar arteries eem to 
be spared. There is evidence that hypertension accelerates 
the atherosclerotic process in the larger cerebral vessels 
and is the most important factor in the development and 
progression of cerebral atherosclerosis. In hypertensive 
subjects, atherosclerosis and atherosclerosis-related hyali- 
nosis have been found in small vessels ( < 2 mm in diame- 
ter), such as the arterioles upplying basal ganglia [44]. 
Clinical and post-mortem studies indicate that athero- 
sclerotic lesions in humans develop preferentially at the 
entrance region of branching arteries and curved seg- 
ments of arteries where blood flow is disturbed and 
eddies are likely to form. Initiation of atherosclerotic le-
sions occurs throughout life. Early lesions can be charac- 
terized either by numerous fat-filled cells (fatty streak- 
type lesions) or by focal intimal thickenings characterized 
by edema, smooth muscle cell proliferation and little or 
no increase in lipid. These two lesion types can occur 
quite independently. The main lipid component ischoles- 
terol esterified with oleic acid. Fibrin deposition may also 
play a significant part in development of the lesion. Once 
some fibrin is formed, it could act as a multipotential 
stimulant of atherogenesis: fibrin acts as a scaffold for 
cell migration, binds fibronectin and thrombin, which is 
itself a potent growth factor, and is a source of fibrino- 
gen-fibrin degradation products which are chemotactic 
for monocytes and stimulate mitogenesis. Furthermore, 
fibrin may play a role in the immobilization of low-densi- 
ty lipoproteins. During the course of life, many fatty 
streaks disappear. However, most adult arteries contain 
at least some small raised lesions with numerous layers of 
fat-filled cells ("fibrous cap") and variable amounts of 
extracellular "atheroma" lipid, usually in the central 
core. 
Lesions exhibiting calcification, ulceration and/or 
thrombosis are called advanced plaques. The factor lead- 
ing to the deposition of calcium in plaques is still un- 
known [63]. Thrombosis ismost likely to occur where the 
plaque narrows the lumen to the greatest degree. The 
most common sites of thrombosis are in the internal 
carotid artery at the carotid sinus in the neck, in the 
vertebral and basilar arteries in the region of their junc- 
tion, at the main bifurcation of the middle cerebral ar- 
tery, in the posterior cerebral artery as it winds around 
the cerebral peduncle and in the anterior cerebral artery 
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as it curves upward over the corpus callosum. Emboli 
may originate from atherosclerotic plaques of the major 
aortocranial vessels, such as the internal carotid artery 
and the vertebral arteries. A main cause of cerebral 
thrombosis the rupture ofintima covering large athero- 
ma, together with subendothelial or subintimal bleeding. 
The separation of plaque edges from underlying tissue 
is also an arterial change causing thrombosis and it 
may occur in fibrocellular intimal thickening even when 
atherosclerotic changes are minute [89]. 
A genetic regulatory mechanism seems to be responsi- 
ble for the extent and location of atherosclerotic lesions, 
which vary according to individual susceptibility. There 
is evidence that different risk factors are associated with 
different locations of lesion [31]. Very few studies have 
investigated risk factors according to extra- or intra- 
cranial location of atherosclerotic lesion. The results of 
two studies [9, 28] were concordant in indicating that 
hypercholesterolemia, heart disease, c[audication and 
Black race were less common in patients with non-embol- 
ic middle cerebral artery occlusion than in patients with 
extracranial occlusive disease. Prevalence of hyperten- 
sion was similar in these two groups of patients. Other 
studies have shown that patients with extracranial carot- 
id stenosis have higher systolic and diastolic blood pres- 
sure, higher plasma cholesterol and triglycerides, a
greater likelihood of being cigarette smokers, diabetics or 
with coronary or peripheral vessel disease than controls 
without carotid lesions. In patients with carotid athero- 
ma [19], the severity of carotid bifurcation atherosclero- 
sis on angiography was correlated positively with total 
cholesterol/high-density lipoprotein cholesterol ratio and 
inversely with high-density tipoprotein cholesterol con- 
centration. These were previously observed in coronary 
atherosclerosis. When considering vascular risk factors in 
relation to presence and severity of extra- or intracranial 
atherosclerosis, Inzitari et al. [30] found that only age and 
sex were related to the presence of intracranial athero- 
sclerosis, while cholesterol values were significantly relat- 
ed to the presence ofextracranial theroclerosis only. On 
analyzing the correlation between risk factors and sever- 
ity of atherosclerotic lesions, both systolic and diastolic 
blood pressure and smoking were significant predictors 
of atherosclerotic severity, but only extracranially. Fur- 
ther observations have confirmed that patients with mid- 
dle cerebral artery lesions differ from those with carotid 
lesions in that they are younger, suffer less frequently 
from ischemic heart disease and have lower cholesterol 
values [31]. 
Ischemic-hypoxic factors 
Cerebrovascular insufficiency, i.e., hypoperfusion of the 
brain caused by various extracranial events and leading to 
reduction of systemic irculation, may result in ischemic- 
hypoxic disturbances and brain infarction, especially in 
the cortical and subcortical watershed areas [22, 70, 85]. 
More widespread changes also occur, as well as localized 
lesions, as in hippocampal involvement [11, 49]. Water- 
shed lesions are sometimes associated with dementia, i.e., 
L. Parneni et al.: Pathogenetic mechanisms in vascular dementia 
ischemic-hypoxic dementia [8, 54, 85], and may in this 
context be revealed by cardiac arrest [3], cardiac arrhyth- 
mia [56] or hypotensive anesthesia [6], and modified by 
stenosis or occlusion of the carotid artery [71, 85]. Car- 
diac arrhythmia [12, 66] and antihypertensive tr atment 
may contribute in the elderly [33] to a process of mental 
decline. Hippocampal hypotensive manifestations may 
also be associated with dementia [74] or amnesia [11, 49]. 
When the boundary lesions are located on the convexity 
of the brain, they are often accompanied by various 
neurological symptoms, such as bibrachial paresis and 
cortical blindness, whereas ubcortically located lesions 
appear to be accompanied by extrapyramidal nd pseu- 
dobulbar symptoms [54]: 
Decreased cerebral blood flow preceding MID, with 
reduced cerebral blood flow values about 2 years before 
the onset of symptoms has been reported [52], which 
suggests that not only thromboembolism but also hypo- 
perfusion may play a role in the pathogenesis of VD. 
Vasculitis 
Several etiologies, such as bacterial, viral, autoimmune, 
connective, fungal, parasitic or miscellaneous can cause 
vasculitis. Vasculitis includes pathological changes of the 
vessel wall, with narrowing and occlusion of the vessel 
lumen, thrombosis with subsequent infarction and, occa- 
sionally, hemorrhages. Although a rare disease, vasculitis 
may be one of the most frequently unsuspected derange- 
ments of the brain vessels, bringing about neurological 
complications and states of confusion. Mental deteriora- 
tion can occur in giant ceil arteritis or granulomatous 
angiitis [35]; polyarteritis nodosa may affect the central 
nervous ystem in 9%-60% of cases [7]; in lupus erythe- 
matosus there are neurological complications in up to 
80% of cases, of which 28% exhibit psychiatric distur- 
bances [69]; patients with rheumatic encephalopathy 
rarely show gross infarction or multiple infarctions. 
Hyperviscosity 
Blood hyperviscosity can be due to elevation of any one 
of the blood viscosity factors: plasma viscosity, packed 
cell volume, red cell aggregation (especially the presence 
of large compact clumps of red cells), the internal viscos- 
ity and rigidity of red cells, the number and rigidity of the 
white cells and the presence of plate[et aggregates. The 
crucial role of blood hyperviscosity is especially apparent 
in the microcirculation. A slowdown of blood flow due 
to occlusion and/or rheological intermittent spasm-like 
conditions leads to deprivation of the tissue of oxygen, 
prevents outflow of metabolites, interferes with commu- 
nication by chemical messengers, results in hypoxia and 
anoxia and initiates blood coagulation, creating a vicious 
circle and inducing the syndromes of blood hyperviscosi- 
ty [13]. The importance of hemorheological parameters 
for the maintenance ofcerebral circulation is known [67] 
and there is evidence for a direct relationship between 
the development and course of ischemic lesions and the 
hemorheological status of the patients [25, 87]. In partic- 
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ular, it has been shown that almost all the hemorheolog- 
ical parameters (erythrocyte aggregation, plasma viscosi- 
ty, erythrocyte deformability) are altered in patients who 
have had lacunar strokes. 
Hemostasis factors 
Despite the fact that thromboembolic disease is known to 
be a contributing factor to the development of VD, no 
systemic study has been carried out to evaluate whether 
or not there is a state of hyperactivity of the hemostatic 
system in patients with VD that might contribute to the 
pathogenesis of the condition. There have been a few 
epidemiological studies, however, of apparently healthy 
middle-aged individuals to investigate whether changes 
in coagulation, fibrinolysis and platelets are associated 
with the later occurrence of ischemic stroke, one of the 
main causes of VD. 
The main coagulation parameter which is predictive of 
cerebrovascular disease in healthy middle-aged individu- 
als is plasma fibrinogen. There is one study, the Gote- 
borg study [15, 80, 83], in which multivariate analysis 
showed fibrinogen levels to be a risk factor for ischemic 
stroke, with a predictive power independent of the contri- 
bution of "conventional" risk factors, such as hyperten- 
sion, smoking and hypercholesterolemia. Thestudy also 
showed a synergistic effect between systolic blood pres- 
sure and hyperfibrinogenemia. It appears that fibrinogen 
is also a predictor of recurrence in patients who have had 
transient ischemic attacks or minor strokes. Higher fi- 
brinogen levels are predictive of ischemic stroke [50], and 
in stroke survivors they are an independent predictor for 
the occurrence of cardiovascular events [51]. In contrast, 
the PLAT study found no association between fibrinogen 
level and the subsequent occurrence of stroke and other 
cardiovascular events in patients with a history of tran- 
sient ischemic attacks [10]. Does pharmacological inter- 
vention affect fibrinogen levels? Dietary modifications 
are not very effective, with the possible exception of in- 
creased dietary intake of fish. The lowering effect of 
drugs such as stanozolol, ticlopidine or pentoxifylline 
needs confirmation. 
The relationship between fibrinolysis parameters and 
the occurrence of stroke has not been extensively investi- 
gated. Baseline fibrinolytic activity was measured in the 
Northwick Park Heart Study [40] and subjects were fol- 
lowed for evidence of myocardial infarction or stroke. 
There was no difference in fibrinolytic activity at entry 
between subjects who did or did not have events. In the 
last few years, more reliable methods for measuring 
specifcally the different components of the fibrinolytic 
system (plasminogen activator, plasminogen activator 
inhibitor) have become available. They should be em- 
ployed in prospective studies to evaluate whether or not 
they can predict the occurrence of stroke. There is little 
information on tests evaluating platelet behavior. In the 
Northwick Heart Park Study only platelet count and 
platelet adhesiveness to glass beads were measured, and 
no correlation with the subsequent occurrence of arterial 
thrombosis was found. 
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There is a compelling need for well-conducted studies 
of the prevention and treatment of VD with drugs that 
affect hemostasis, because no controlled trials are avail- 
able. A pilot study [43] with aspirin (325 mg daily for 
3 years) was promising and in two small series [4, 47] 
elderly patients with cerebrovascular dementia treated 
with pentoxifylline had less deterioration of psychobe- 
havioral scores than those treated with placebo. One 
study has proposed [79] the use of anticoagulant therapy 
in senile and presenile dementia, an approach that needs 
further confirmation. 
Lipohyalinosis 
This form of arteriolopathy may be a major determinant 
of lacunar infarction, as related to chronic arterial hyper- 
tension. Lipohyalinosis can be a homogeneous or a gran- 
ular eosinophilic deposit within the connective tissue of 
the vessel wall. It is usually segmental and is associated 
with parietal fibrosis. When the arteriole becomes oc- 
cluded, a small infarct (a lacune) is produced, because the 
perforators are end-territory vessels. Among 50 lacunes 
from an autopsy series, Fisher [18] found that lipohyali- 
nosis was responsible for 40 of the 45 occlusions of the 
appropriate arteriole. However, the lacunes associated 
with lipohyalinosis are very small, and more than 80% of 
the patients may remain symptomless [5, 18]. 
Cerebral amyloid angiopathy 
The term amyloidosis covers a group of diseases charac- 
terized by deposition of abnormal fibrillary proteins in 
the extracellular and intracellular spaces. All types of 
amyloid fbrils have a/~-pleated sheet secondary structure 
and a green birefringence under polarized light after 
staining with Congo red. Systemic and localized forms of 
amyloidosis are known and cerebral amyloidosis is the 
most frequent localized form. Vascular amyloid is present 
in the walls of leptomeningeal nd parenchymal cortical 
arteries and arterioles in several diseases, such as Alz- 
heimer's disease, Down's syndrome, sporadic cerebral 
amyloid angiopathy and Icelandic and Dutch hereditary 
cerebral hemorrhage with amyloid. Amyloid deposits are 
also present in neurofibrillary tangles and senile plaques. 
The vascular amyloid of the Dutch hereditary cerebral 
hemorrhage and Alzheimer's disease is composed of 39 
residues, 3 residues horter than plaque amyloid protein 
of Alzheimer's disease, while amyloid of the Icelandic 
type is related to another class of amyloid proteins, the 
cystatin C protein family. 
In Alzheimer's disease the cellular origin of amyloid is 
consistent, he gene of its precursor, i.e., of amyloid pre- 
cursor protein, being expressed in many tissues. Further- 
more, larger neurons contain large amounts of mRNA 
encoding for amyloid precursor protein, suggesting that 
neurons are the most likely source for amyloid deposi- 
tion. The specific vascular deposition of similar protein in 
familial and sporadic cerebral amyloid angiopathy sug- 
gests a hematogenous origin of amyloid from a soluble 
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precursor [20]. In the vessels, amylo id  causes thickening 
of the vessel wall, which may then undergo hyaline degen- 
eration, f ibrinoid necrosis, aneurysmal  di latat ion and 
prol i ferative vascular changes. These changes might be 
the basis of the anatomical  and functional alterat ions 
leading to neurological and psychobehavioral  distur- 
bances of VD. 
Concluding remarks 
Thromboembol i sm with mult iple cerebral infarcts was 
regarded for 2 decades as the main pathogenetic pathway 
of  VD, with MID as its clinical counterpart .  Based on the 
present findings, a more compl icated approach to VD is 
called for, taking into account various vascular mecha- 
nisms and their combined effects. In this way, categories 
other than the MID entity may be detected. 
Even though a pure MID entity with dementia caused 
by vast destruct ion of  the brain parenchyma evidently 
exists, infarction found in dement ia  patients may more 
often be a marker  of  than the direct cause of the disease. 
Subcort ical  white matter  d isorder with or without in- 
farcts is one important  substrate of  VD, and it can be 
produced by various vascular mechanisms. Hypoper fu-  
sion may be one of  the most important  of  these patho-  
genic pathways producing dementia,  either from global 
brain ischemia or from restricted ischemia in watershed 
territories, including the periventr icular white matter.  It 
is important  o find a biological marker  for this vascular 
white matter  damage. 
F rom the cl inician's point of  view the variety of  vascu- 
lar mechanisms involved in VD might al low different 
therapeutic strategies. The treatment of  VD may become 
a question not only of  preventing thromboembol i sm but 
also o f  opt imizing cerebral perfusion. 
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